Neurotech International Ltd

NEW
ASX:NTI (Australia)  
A$ 0.017 (0%) Jul 15
At Loss
P/B:
3.40
Market Cap:
A$ 22.40M ($ 15.71M)
Enterprise V:
A$ 16.06M ($ 11.26M)
Volume:
1.11M
Avg Vol (2M):
2.07M
Trade In:
Volume:
1.11M
At Loss
Avg Vol (2M):
2.07M

Business Description

Description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
No Debt
Equity-to-Asset
0.86
Interest Coverage
No Debt
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
64.46
9-Day RSI
63.76
14-Day RSI
62.97
6-1 Month Momentum %
-7.14
12-1 Month Momentum %
-31.58

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
7.3
Quick Ratio
7.3
Cash Ratio
6.8

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-14.6
Shareholder Yield %
-14.95

Profitability Rank

Name Current Vs Industry Vs History
ROE %
-79.29
ROA %
-70.09
ROIC %
-4051.28
ROCE %
-227.74

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio
3.4
Price-to-Tangible-Book
1.7
EV-to-EBIT
-1.45
EV-to-EBITDA
-1.45
EV-to-FCF
-5.28
Earnings Yield (Greenblatt) %
-68.82
FCF Yield %
-13.26

Financials

ASX:NTI's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Neurotech International Ltd Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.004
Beta 0.7849
3-Year Sharpe Ratio -0.25
3-Year Sortino Ratio -0.37
Volatility % 61.95
14-Day RSI 62.97
14-Day ATR (A$) 0.001208
20-Day SMA (A$) 0.0153
12-1 Month Momentum % -31.58
52-Week Range (A$) 0.01 - 0.029
Shares Outstanding (Mil) 1,317.74

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Neurotech International Ltd Filings

Filing Date Document Date Form
No Filing Data

Neurotech International Ltd Stock Events

Financials Calendars
Event Date Price (A$)
No Event Data

Neurotech International Ltd Frequently Asked Questions

What is Neurotech International Ltd(ASX:NTI)'s stock price today?
The current price of ASX:NTI is A$0.02. The 52 week high of ASX:NTI is A$0.03 and 52 week low is A$0.01.
When is next earnings date of Neurotech International Ltd(ASX:NTI)?
The next earnings date of Neurotech International Ltd(ASX:NTI) is .
Does Neurotech International Ltd(ASX:NTI) pay dividends? If so, how much?
Neurotech International Ltd(ASX:NTI) does not pay dividend.

Press Release

Subject Date
No Press Release

Articles on Neurotech International Ltd

No articles.